Literature DB >> 30680202

Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report.

Suguru Shirotake1, Go Kaneko1, Koji Nagata2, Masafumi Oyama1, Koshiro Nishimoto1.   

Abstract

The present case report describes a case of left renal clear cell carcinoma with brain, lung, para-aortic, and lymph node metastases (cT1bN1M1) in a 52-year-old Japanese male. The patient received sequential anticancer treatments with pazopanib, everolimus, and axitinib, but exhibited treatment-resistant tumor growth. Treatment with nivolumab resulted in a complete response in metastatic sites. However, the residual renal tumor, which was enhanced by contrast medium, required radical nephrectomy. Pathological analyses of the renal tumor revealed that it consisted of fibrotic and lymphocyte-infiltrated tissues in which morphological cancer cells were not detected. The majority of lymphocytes were cluster of differentiation (CD)8-positive, suggesting that cancer cells were attacked by these lymphocytes. Retrospective analyses of renal cell carcinoma tissues, which were biopsied before the anticancer treatment, revealed their infiltration by CD8-positive T cells. To the best of our knowledge, this is the first case report to examine renal tissue prior to and following treatment with nivolumab using immunohistochemical analysis.

Entities:  

Keywords:  cluster of differentiation 8-positive T cells; complete response; immunomodulatory activity; metastatic renal cell carcinoma; nivolumab

Year:  2018        PMID: 30680202      PMCID: PMC6327208          DOI: 10.3892/mco.2018.1779

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  9 in total

1.  Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report.

Authors:  Suguru Shirotake; Yuta Umezawa; Takashi Okabe; G O Kaneko; Kent Kanao; Koshiro Nishimoto; Masafumi Oyama
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma.

Authors:  Yadav Pandey; Aasiya Matin; Brannon Broadfoot; Anuradha Kunthur
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-01-30

3.  Long-term Response After Stopping Immunotherapy in a Patient With Metastatic Renal Cancer.

Authors:  Bogdan Haineala; Anca Zgura; Camelia Diaconu; Claudia Mehedintu; Xenia Bacinschi; Rodica Maricela Anghel
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

4.  Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.

Authors:  Hiroki Hagimoto; Soki Kashima; Kazuki Doi; Shintaro Nakayama; Takanori Sano; Satoshi Imai; Tomihiko Yasufuku; Mototsugu Muramaki; Yuji Yamada
Journal:  IJU Case Rep       Date:  2020-10-05

5.  Rapid progression of recurrent disease in a patient with renal cell carcinoma with vaginal metastasis.

Authors:  Mizuki Hisano; Renpei Kato; Hiroaki Itamochi; Tomohiko Matsuura; Shigekatsu Maekawa; Yoichiro Kato; Mitsugu Kanehira; Ryo Takata; Tsukasa Baba; Wataru Obara
Journal:  IJU Case Rep       Date:  2020-07-07

6.  Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports.

Authors:  Matthew D Tucker; Kathryn E Beckermann; Jennifer B Gordetsky; Giovanna A Giannico; Nancy B Davis; Brian I Rini
Journal:  Front Oncol       Date:  2020-12-22       Impact factor: 6.244

Review 7.  From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.

Authors:  Jonathan Anker; Justin Miller; Nicole Taylor; Natasha Kyprianou; Che-Kai Tsao
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

Review 8.  Immunotherapy in Renal Cell Carcinoma: The Future Is Now.

Authors:  Antoine Deleuze; Judikaël Saout; Frédéric Dugay; Benoit Peyronnet; Romain Mathieu; Gregory Verhoest; Karim Bensalah; Laurence Crouzet; Brigitte Laguerre; Marc-Antoine Belaud-Rotureau; Nathalie Rioux-Leclercq; Solène-Florence Kammerer-Jacquet
Journal:  Int J Mol Sci       Date:  2020-04-05       Impact factor: 5.923

9.  A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.

Authors:  Hana Studentova; Anezka Zemankova; Martina Spisarova; Daniela Skanderova; Zbynek Tudos; Bohuslav Melichar; Vladimir Student
Journal:  Medicina (Kaunas)       Date:  2022-02-23       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.